# Highlights of This Issue 2503

## SPECIAL FEATURES

### CCR Translations

- **2505** Minimal Residual Disease in Breast Cancer: In Blood Veritas  
  Giulia Siravegna and Alberto Bardelli  
  *See related article, p. 2643*

### Molecular Pathways

- **2508** Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer  
  Alastair M. Thompson
- **2516** Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer  
  Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

### CCR Focus

- **2524** The Language of Pharmacodynamics  
  Susan E. Bates
- **2525** Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine  
  William Douglas Figg and David R. Newell
- **2530** Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology  
  Daniel L. Hertz and Howard L. McLeod
- **2541** Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics  
  Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo
- **2553** Circulating Tumor Cells: A Multifunctional Biomarker  
  Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono
- **2569** In Vivo Imaging as a Pharmacodynamic Marker  
  Astrid A.M. van der Veldt and Adriaan A. Lammertsma
- **2578** Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations  
  Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment
- **2587** Pharmacodynamic Biomarkers: Falling Short of the Mark?  
  Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

### HUMAN CANCER BIOLOGY

- **2595** FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression  
  Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie
- **2607** Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration  
  Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udaï S. Kammula
- **2617** miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression  
  Xuanyu Chen, Xuegang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang
- **2631** Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2-Negative Feedback Loop Mechanism  
  Yan-Xia Lu, Li Yuan, Xiao-Bei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Iloculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhukowicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem

ABOUT THE COVER
The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.